Abstract
Chronic hepatitis C is a leading cause of liver-related morbidity and mortality worldwide. If untreated, chronic hepatitis C can progress to advanced liver fibrosis, cirrhosis, liver failure, hepatocellular carcinoma and death. Until recently, treatment of hepatitis C predominantly constituted an immunomodulatory agent, peg-interferon-alfa and ribavirin. In 2011, the first class of directly acting antiviral agents, HCV NS3/4A serine protease inhibitors, was added to peg-interferon-alfa and ribavirin with increased efficacy. In the past year, an NS5B inhibitor, sofosbuvir, has emerged as a potent agent with pangenotypic efficacy, resulting in the first interferon-free regimen for the treatment of hepatitis C. This review summarizes the data that resulted in regulatory approval of sofosbuvir and highlights the future of hepatitis C therapy with sofosbuvir as the backbone of a highly effective antiviral regimen.
References
Aug 31, 2010·The Journal of Biological Chemistry·Eisuke MurakamiPhillip A Furman
Sep 18, 2010·Journal of Medicinal Chemistry·Michael J SofiaPhillip A Furman
Sep 21, 2011·Annals of Internal Medicine·Vincent Lo ReRobert Gross
Mar 21, 2012·Antimicrobial Agents and Chemotherapy·Angela M LamPhillip A Furman
Nov 28, 2012·Journal of Hepatology·Maribel Rodriguez-TorresJay Lalezari
Dec 25, 2012·Antimicrobial Agents and Chemotherapy·Jill DenningWilliam T Symonds
Jan 4, 2013·The New England Journal of Medicine·Edward J GaneM Michelle Berrey
Mar 9, 2013·Gastroenterology·Jianmeng ChenDebra Birnkrant
Mar 9, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Stefan Zeuzem, Federico J Mensa
Mar 19, 2013·The Lancet Infectious Diseases·Eric LawitzAndrew Muir
Mar 19, 2013·Lancet·Kris V KowdleyIra M Jacobson
Apr 24, 2013·The New England Journal of Medicine·Ira M JacobsonUNKNOWN FUSION Study
Apr 24, 2013·The New England Journal of Medicine·Eric LawitzEdward J Gane
Aug 29, 2013·JAMA : the Journal of the American Medical Association·Anuoluwapo OsinusiShyamasundaran Kottilil
Sep 10, 2013·Journal of Viral Hepatitis·E B Tapper, N H Afdhal
Nov 12, 2013·Lancet·Eric LawitzFernando E Membreno
Nov 23, 2013·Gastroenterology·Edward J GanePhillip S Pang
Jan 17, 2014·The New England Journal of Medicine·Mark S SulkowskiUNKNOWN AI444040 Study Group
Apr 12, 2014·The New England Journal of Medicine·Kris V KowdleyUNKNOWN ION-3 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-2 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-1 Investigators
May 6, 2014·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN VALENCE Investigators
Jun 12, 2014·Expert Review of Clinical Pharmacology·Brian LamZobair Younossi
Jul 20, 2014·JAMA : the Journal of the American Medical Association·Mark S SulkowskiUNKNOWN PHOTON-1 Investigators
Aug 1, 2014·Lancet·Eric LawitzIra M Jacobson
Citations
Nov 13, 2015·Expert Review of Gastroenterology & Hepatology·L TangS Kottilil
Feb 24, 2016·Expert Opinion on Pharmacotherapy·Elana S RosenthalMichael A Polis
Sep 15, 2016·Hepatology International·Chandana PapudesuShashwatee Bagchi
Apr 28, 2017·PloS One·Yuely A CapilenoCatherine Van Overloop
Mar 1, 2016·MedChemComm·Jiahong LiPiet Herdewijn
Oct 21, 2017·Expert Opinion on Investigational Drugs·Ameer Abutaleb, Shyamasundaran Kottilil
Nov 12, 2015·World Journal of Gastrointestinal Pharmacology and Therapeutics·Shogo OhkoshiSatoshi Yamagiwa
Dec 9, 2016·Hepatology International·Rebecca LeeEleanor Wilson
Jan 29, 2016·World Journal of Gastroenterology : WJG·Sadhna DhingraSwan N Thung
Nov 8, 2018·Medicina·Saba Khaliq, Syed Mohsin Raza
Feb 11, 2021·PloS One·Sara Majd JabbariSadaf G Sepanlou
Apr 2, 2021·European Journal of Clinical Pharmacology·H A ElmekawyF Elbarbry
May 1, 2021·Viruses·Evelyn J FrancoAshley N Brown
Jul 27, 2021·Virusdisease·Chayan BhattacharjeeAparna Mukhopadhyay
Aug 10, 2017·Journal of Medicinal Chemistry·Youcef MehellouJan Balzarini